Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus ZYLET.
KENALOG IN ORABASE vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination (Ophthalmic)